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Contraction and force generation in muscle occurs via interactions between thick and thin 
filaments within the subcellular sarcomere structure of fused muscle cells (myofibrils). This 
heavily regulated process involves the coordinated efforts of tropomyosin, the troponin 
complex, myosin binding protein C and other accessory proteins. The regulation of muscle 
contraction is important for both contraction and relaxation, for example in the heart, the 
former leads to pumping and the latter refilling of the cardiac chambers. The focus of this 
thesis is the relaxation of muscle, which is highly relevant to diseases such as HCM. Using 
single molecule microscopy, the dynamics of thin filament activation have been measured 
in a metastable condition, between contraction and relaxation. This provides a molecular 
insight into both processes at the same time. Here I have developed a suite of analysis 
programs to investigate how the muscle regulatory system relaxes. Analysis of events has 
revealed that myosin molecules attached to regulated thin filaments are released in a 
concerted fashion, a process we call catastrophic collapse. With this understanding and 
new analytical tools, we are now in a position to analyse mutations associated with HCM to 























7.1. The Muscular System 
7.1.1. Muscle Types 
 
Muscle is found throughout the various motile and non-motile systems in every animal, 
ranging in purpose from enabling digestion, enabling gross movements and pumping blood. 
Its ubiquitous presence in organisms illustrates its physiological importance but also 
provides reasoning for its high conservation (Ng et al., 1985), for example, actin is 
considered as a universal polymerisation machine (Gunning et al., 2015a) and in higher 
vertebrates the proteins share a ≥ 94% sequence identity (Zhu et al., 2013; Vedula and 
Kashina, 2018).  
Depending on role, three types of muscle exist: skeletal, cardiac, and smooth. At a glance, 
the arrangement of each sarcomere seems similar, however, their location within the body 
and the addition of accessory proteins differs between them and ultimately determines 
their contractile function (Sweeney and Hammers, 2018). Skeletal muscle is a voluntary 
muscle that attaches to bones via tendons, it is the muscle group that coordinates the 
movement of your body. Each muscle cell (myocyte) is multinucleated and has a striated 
appearance due to the highly organised pattern of proteins sarcomeres (discussed later). 
The second muscle type, cardiac, is found solely in the heart and each cardiomyocyte must 
work in a synchronised fashion to coordinate continuous contraction. Finally, smooth 
muscle contracts involuntarily, serving many functions involving visceral organs such as 
digestion in your intestines, gastrointestinal (GI) tract (peristalsis) and regulation of blood 
pressure. Within a myocyte there are thousands of sarcomeres working in a synchronised 
fashion to contract and relax due to the presence of Ca2+ ions and the phosphorylation of 
the regulatory and essential light chains on muscle myosin II (Dillon et al., 1981; Hai and 
Murphy, 1989). 
 
7.1.2. Muscle Contraction 
 
Muscle contraction is dependent on the subtype of muscle within the body. The 
mechanism differs between striated muscle and smooth muscle. 
Striated muscle has contraction due to excitation-contraction coupling (Kuo and Ehrlich, 
2015). This is where neurotransmitters depolarise membranes, influencing receptors to 
increase local calcium concentrations which ultimately leads to contraction of the muscle. 
These neurotransmitters bind to receptors on the motor end plate and causes an influx of 
sodium (Na+) ions which depolarises the membrane across the surface of the muscle tissue 
and depolarises the T-tubule system. The depolarisation of the T-tubules triggers a shift in 
the resting membrane potential of the muscle, and it turns on the voltage gated channels 
causing further depolarisation. This causes a stimulation of L-type calcium channels which 
opens Ryanodine Receptor (RyR) 1 or Ryanodine Receptor (RyR) 2 channels to release of 
calcium (Ca2+) ions from the sarcoplasmic reticulum to activate the skeletal or cardiac 
muscle, respectively (Bootman, 2012). Ultimately this influx of Ca2+ leads to interactions 
with troponin C allowing conformational change of the tropomyosin and in turn exposing 
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the myosin binding sites on actin for the myosin heads so that activation of thin filament 
can occur. 
Smooth muscle receives its excitation via the autonomous nervous system which leads to 
an intracellular calcium influx which causes contraction of the muscle. This is similar to 
striated muscle where depolarisation causes activation of L-type calcium channels which 
leads to an increase in intracellular calcium and thus contraction of muscle. However, there 
is another pathway that is responsible for muscle contraction, which involves the activation 
of G-coupled (Gq) receptors which leads to the production of inositol 1,4,5-triphosphate 
(IP3) which is made by the protein phospholipase C. IP3 is an ubiquitous secondary 
messenger which can open IP3 receptors on the surface of the sarcoplasmic reticulum. This 
in turn causes an increase in intracellular calcium which is the driving force for muscle 
contraction (Bezprozvanny et al., 1991; Finch et al., 1991). 
 
7.1.3. Sliding Filament Theory 
 
This description of muscle contraction dates back to 1954 where two studies by A. F. 
Huxley and R. Niedergerke and H. E. Huxley and J. Hanson describe the process of muscle 
contraction visualised via high resolution microscopy (Huxley and Niedergerke, 1954; 
Huxley and Hanson, 1954). In the former study, they initially show the striated pattern of 
the muscle tissue is what we now know to be the ultrastructure of thick and thin filaments. 
This allowed measurements of the sarcomere length to be made before and after isotonic 
contractions (Huxley and Niedergerke, 1954). These measurements allow the differences to 
be highlighted in the band sizes e.g. I-bands become narrower during contraction. The 
second study outlines the changes in the cross striations during contraction and stretching 
of the muscle, various conditions were applied, for example, using concentrated vs dilute 
ATP or controlling shortening by holding both ends of the muscle fibre (Huxley and Hanson, 
1954). These studies were done via light microscopy and verified by electron microscopy 
and similar results were also seen via X-ray diffraction studies (Hanson and Huxley, 1953).  
Essentially, this theory suggests a simple model that describes the changes of the cross 
striations during muscle contraction. It states that in the sarcomere there are two bands, 
where the I band contains non-overlapping actin filaments and the A band contain myosin 
and both non and the overlap region. During contraction, the I band shortens, and the A 
band remains constant, so visually the I band slides over the A band, hence the sliding 
filament model. 
7.1.4. Three-state model of thin filament activation 
 
The three-state model of thin filament activation (Maytum et al., 1999) describes the 
propensity of myosin to form an actomyosin complex. These affinities directly correspond 
to the positioning of tropomyosin. The positioning of tropomyosin is influenced by troponin 
sensing an influx in local calcium levels. This model states that the three states of activation 
are the following: blocked, closed and open. Where, the blocked state involves 
tropomyosin completely blocking all the myosin binding sites along thin filament. The 
closed state is where there is an increased level of calcium which is sensed by troponin 
allowing tropomyosin to move more freely. The open state is where myosin has a high 
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affinity. This is where all the components of the muscular system are present and working 
together so that myosin can bind strongly to actin whilst tropomyosin shifts to allow lateral 
activation of thin filament as illustrated in Figure 1.  
 
 
Figure 1 - The three-state model of thin filament activation. 
Illustrating two transitions between the blocked and closed states and the closed and open states. 
The blocked state shows tropomyosin completely covering myosin binding sites located on actin, 
there are no other components of the muscular system that are present such as calcium, myosin and 
ATP. The blocked and closed states are in equilibrium and in the presence of Ca2+ ions, the blocked 
state can transition to the closed state, where calcium can activate the troponin complex allowing 
flexibility of tropomyosin, exposing the myosin binding sites. It is where the addition of ATP and 
myosin can cause the transition from the closed state to the open state where myosin can bind to 
the myosin binding site located on actin and induce thin filament activation. Illustration is not to 
scale as myosin motor domain is 130 kDa and each actin monomer is 42 kDa. 
7.1.5. Force Generation 
 
The interactions between actin and myosin in the presence of calcium and ATP generate 
force and motion. This motion generated is from a process called the crossbridge cycle 
which was derived from the Lymn-Taylor cycle (Lymn and Taylor, 1971). The crossbridge 
cycle consists of four steps. The first step consists of crossbridge formation, whereby the 
activated myosin can bind to actin to form a stable actomyosin complex. Myosin is 
activated by ATP binding to the ATPase site on the myosin head so that ATP can be 
hydrolysed into ADP and inorganic phosphate (Pi). The next step is where the hydrolysis of 
ATP leads to ADP and inorganic phosphate to be released causing a power-stroke to occur 
allowing myosin to create a rowing like movement across the actin (Holmes, 1997; Geeves 
and Holmes, 1999). Now that the ATPase site on myosin is free, local ATP is able to rebind 
to that site and causes the myosin from the crossbridge to detach from the actin. Finally, 
reactivation of the myosin head must occur via the hydrolysis of ATP to complete the 
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crossbridge cycle, this is illustrated in Figure 2. The forces generated from this crossbridge 
cycle have been extensively studied over the years via in vitro motility assays (Homsher et 
al., 1996; Greenberg and Moore, 2010), X-ray diffraction studies (Irving et al., 1992) and 
force-tension experiments (Karatzaferi et al., 2004). 
 
Figure 2 - The crossbridge model of muscular contraction, illustrating the hydrolysis of ATP.   
This schematic (not to scale) illustrates the crossbridge cycle in muscular contraction. Where 1) 
shows ATP binding to the myosin head, whereby in 2) hydrolysis of ATP activates the myosin head 
allowing a crossbridge to form, but as ADP and Pi are released, a power stroke occurs – this is seen in 
3) where the myosin head has a change in angle thus moving actin filament along. Finally, in 4) the 
myosin head is reactivated in the presence of ATP. 
7.2. The Sarcomere 
7.2.1. Structure & Function 
 
The sarcomere is the smallest contractile unit within muscle. This repeating arrangement of 
thick and thin filament allows a length-tension relationship that is responsible for muscular 
contraction (Au, 2004). In its most relaxed state, force tension experiments have shown the 
sarcomere to be a length of 2.4 µm (Johnston et al., 2016). These experiments play on the 
structure of the sarcomere and highlight the function of each component. Initially they 
show that ATP hydrolysis is done by the thick filament, thin filament is activated by Ca2+ 
and other regulatory proteins such as Myosin Binding Protein C, Tropomyosin, and the 
Troponin Complex interact with each other at varying degrees and contribute to the 
regulation of muscular contraction. More recent studies shows that MyBP-C governs 
interactions with both thick and thin filament (Heling et al., 2020) and tropomyosin along 
with the troponin complex has various degrees of interactions with thick and thin filament 






7.2.2. Calcium role of regulation of contraction 
 
Every muscle requires calcium for contraction, it is the main signalling molecule which 
controls contraction and relaxation of the different muscle types, in the absence of calcium 
there is no interaction between actin and myosin (Szent-Györgyi, 1975). Calcium is released 
due to a change in stimuli which is caused by neurotransmitter release which in turn 
interacts with receptors to release stores of calcium in the sarcoplasmic reticulum. 
Depending on the tissue type as described earlier, calcium can interact in different ways 
such as directly associating with Troponin C and causing conformational change in 
tropomyosin, or calcium can interact with G-coupled receptors and release IP3 which 
causes even more of an influx of calcium which then can activate myosin light-chain kinase 
to initiate muscle contraction (Berchtold et al., 2000).  
To regulate Ca2+ homeostasis, calcium is pumped back from the cytosol of the myocyte into 
the sarcoplasmic reticulum via the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) so 
that the muscle can relax (Periasamy et al., 2008) and be ready for another potential 
activation.  
 
7.3. Thin Filament 
7.3.1. Actin  
 
Actin was discovered and successfully isolated by Straub in 1942 from myosin which usually 
is in a complex called actomyosin. The 42-kDa protein monomer forms polar, double 
stranded helical filaments (F-actin). Actin has many purposes in eukaryotic organisms 
(Dominguez and Holmes, 2011) however, more specifically in muscle, its purpose is to allow 
muscle contraction via its interactions with myosin and accessory proteins. The filament 
has two ends, termed barbed and pointed and they represent what side is more active in 
terms of elongation, studies have shown that the pointed end is more active in its rate of 
elongation and leads to actin treadmilling (Wegner and Isenberg, 1983). X-ray 
crystallography and electron microscopy studies have shown the detail in structure of F-
actin, and it does confirm its two chained right-handed helix conformation(Dominguez and 
Holmes, 2011). 
Actin has ATPase activity which is required during filament assembly and allows the cross-
bridge cycle to occur when an interaction between myosin has been made. In the cross-
bridge cycle, as myosin binds to actin in the presence of ATP, ATP is then hydrolysed into 
ADP whilst releasing inorganic phosphate. This causes a conformational change in myosin 
allowing it to generate force for the power stroke and ultimately moves actin along 







Tropomyosin, discovered in 1946 by Kenneth Bailey is a long 65 kDa protein dimer which 
has two alpha helices (32.5 kDa each) which are wound in a rigid coiled coil orientation 
(Bailey, 1946). It forms head to tail polar filaments alongside the thin filament (Gunning et 
al., 2015b). Tropomyosin has two striated muscle isoforms (α and β) which polymerise in 
low ionic strength solutions (Ooi et al., 1962; Paulucci et al., 2004). It polymerises along the 
major groove of actin filaments and correct spacing of the homodimer αβ complex allows 
for cooperative activation of thin filament (Hitchcock-DeGregori and An, 1996; Schevzov et 
al., 2012). 
The shape and conformation of tropomyosin has the primary roles of stabilising thin 
filament and regulating muscle contraction via steric hinderance. Tropomyosin has a strong 
affinity to the thin filament and it has been confirmed via deletion studies (Hitchcock-
DeGregori et al., 2001), the highly conserved N-terminal half of tropomyosin’s period 5 is 
home to the internal region responsible for this (Brown et al., 2005),(Hitchcock-DeGregori 
and Singh, 2010). 
Studies have shown that tropomyosin has two states, essentially “on” and “off” which is 
influenced by the presence of troponin which leads to the cooperative binding of S1 
(Geeves and Lehrer, 1994). Tropomyosin has interactions with the C-terminal domain of TnI 
which causes displacement of tropomyosin and allows myosin interaction with actin 
(Galińska-Rakoczy et al., 2008; Lehman et al., 2009). 
 
7.3.3. Troponin Complex 
 
Troponin was discovered in 1963 by Setsuro Ebashi which led to the investigation of 
calcium regulation during muscular contraction. The troponin complex is a large multi 
subunit complex with a size of about 80 kDa (Ohtsuki and Morimoto, 2013). Each subunit of 
troponin: Troponin I (TnI), Troponin C (TnC) and Troponin T (TnT), has a different structure 
and function and studies have now shown the structure and function of each component of 
the troponin complex using X-ray crystallography (Takeda, 2005). Each troponin subunit 
alongside tropomyosin allows the inhibition of contraction of thin filament. 
Troponin I is a globular protein around 37 kDa (cardiac molecular weight (Dasgupta and 
Wahed, 2014)) and has been classed as the inhibitory subunit of the complex, as it inhibits 
the actin-myosin interaction (Perry, 1999; Geeves, 2012). TnI has multiple functions such as 
inhibiting myosin binding to actin, inhibiting actomyosin ATPase and reversal of inhibition 
by activation of TnC (Geeves et al., 2000; Ohtsuki and Morimoto, 2013).  
Troponin C is a small globular protein from the calmodulin family that is around 18 kDa in 
size. It has the role of binding to Ca2+ ions and interacting with troponin I to stop its 
inhibitory effects in the presence of Ca2+. Skeletal troponin C has four binding sites from I – 
IV and they have varying affinities to Ca2+, whereby I-II have low affinities so that it can 
respond to larger changes in Ca2+ concentrations during muscle contraction and III-IV have 
higher affinities to Ca2+ which mean they are always active due to physiological ionic 
conditions (Herzberg et al., 1987).  
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Troponin T has the role of binding to tropomyosin and anchoring troponin I and C subunits 
to the thin filament (Marques and de Oliveira, 2016). As the organiser of the complex, 
around 31-36 kDa and 18 nm in diameter (Tobacman, 1996; Perry, 1998) it interacts with 
tropomyosin and orchestrates the inhibitory function of the complex. Troponin T interacts 
physiologically to the I and C subunits and causes an effect on calcium sensitivity of the 
actomyosin MgATPase. Ultimately, the troponin complex hand in hand with tropomyosin 
has the regulatory role of muscle contraction. 
 
7.4. Thick Filament 
 
The myofilament contains the primary motors that drive muscle contraction – these motors 
are thick filament. Thick filament within the sarcomere is also known as muscle myosin II 
with a motor domain (about20 nm long) and an alpha helical coiled myosin rod (150 nm 
long). Alongside the core head, neck, and tail structure of myosin, within the neck region of 
muscle myosin II there are other components such as the essential light chain and 
regulatory light chain, these are the calcium sensing components of thick filament (Fusi et 
al., 2016). Thick filament has a very organised repeating structure whereby every 43 nm 
along the filament there are three pairs of myosin heads around the myosin circumference, 
this is termed a quasi-helical organisation (Irving, 2017). Regulation of thick filament is 
done by the accessory protein – Myosin Binding Protein C (MyBP-C), which packs itself 
alongside the 9 myosins in the 43 nm repeating pattern allowing its C-terminal domain to 
interact with the N-terminal domain of myosin (Ratti et al., 2011; Wang et al., 2016; Heling 
et al., 2020). 
Thick and thin filament in the presence of Ca2+ expose myosin binding sites located on the 
thin filament and in turn cause thick filament to bind and hydrolyse ATP to cause a cross-
bridge cycle. The interactions between these two work under a cooperative fashion and the 
generation of force from these interactions are dependent on many factors. 
 
7.5. Project Outline 
 
The activation of thin filament has been studied extensively over the years and more 
recently, single molecule studies have shown the cooperative activation of thin filament 
(Desai et al., 2015; Longyear et al., 2017; Inchingolo et al., 2019). It is hypothesised that this 
activation is a cooperative process, whereby two myosin heads are required to laterally 
activate thin filament (Desai et al., 2015). This hypothesis falls in line with the current three 
state model (McKillop and Geeves, 1993), ensemble kinetics (Maytum et al., 1999) and 
structural studies (Vibert et al., 1997). However, this is not the only component of the 
muscular system, relaxation is the second and equally necessary part to muscular 
contraction and shouldn’t merely be seen as a passive process (Biesiadecki et al., 2014).  
Previous studies have indicated that there may be a phenomenon termed catastrophic 
collapse (Desai et al., 2015; Inchingolo et al., 2018), whereby relaxation of thin filament is 
not only seen as a stochastic process, but more concerted events of thin filament 
deactivation occur. By using the single molecule tightrope assay we are able to visualise 
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these events and to interpret them, statistical validation has been done via the Reversible 
Jump Markov Chain Monte Carlo (RJMCMC) model (Inchingolo et al., 2018). To simplify the 
data analysis so that it is more applicable to wider data sets, I have developed a new 
analysis protocol to confirm the presence of catastrophic collapse. Using this analysis, we 
are able to hypothesise that the concerted release of myosin is an active, coordinated 
process which provides complete relaxation of muscle. Studies have shown impairment of 
muscular relaxation in diseases such as hypertrophic cardiomyopathy (HCM) (Tardiff, 2005; 
Li et al., 2012), HCM is a common phenotype for these molecular insults and we believe 
this process could provide a molecular explanation for it.  
My project aims are as follows: 
1. To be able to extract and purify actin and muscle myosin II from Chicken Pectoralis 
2. To be able to fluorescently label and purify S1 myosin mNeonGreen 
3. To conduct single molecule fluorescent microscopy of regulated thin filament 
4. Develop a new workflow for data analysis to track the catastrophic collapse of 
myosin clusters on regulated thin filament 
8. Experimental Methods 
 
8.1. Extraction and Purification of Myosin 
8.1.1. Extraction of Muscle Myosin II from Chicken Pectoralis 
 
Myosin was prepared from chicken pectoralis. Pectoralis tissue was sourced from the local 
butchers in the morning, excess tendons, fats and other tissue were removed, and it was 
rinsed with 0.2 M EDTA. The tissue was cut into small pieces and then went through the 
meat grinder. After this was done, 2 ml of buffer A was added per g of tissue and it was 
stirred gently (to avoid air bubbles) with an overhead stirrer for 12 minutes precisely. This 
reaction was stopped by adding cold ddH2O up to 2 L. This 2L solution was filtered through 
four layers of cheesecloth and the solution was retained in a 5 L beaker. Cold ddH2O was 
added to 5 L and gently stirred to solubilise – then the stir bar was removed so that the 
myosin could then precipitate after 3 hours in the cold room. The remaining pulp was used 
for the actin acetone powder preparation. The supernatant was carefully siphoned off 
(Stage 1 in figure 8) and the precipitate was then centrifuged at 7800 rpm (10,750 x g) in a 
Beckman Coulter JA-10 at 4oC for 10 minutes. The supernatant was discarded (Stage 2 in 
figure 8), the pellet from this centrifugation step was then resuspended in 15 ml of buffer B 
(Stage 3 in figure 8) and dialysed overnight against 4 L of buffer C at 4oC.  
Day 2 involved adding equal amounts of ddH2O to the dialysed solution in a tared beaker. 
This was gently stirred for 30 minutes to precipitate the actomyosin (Stage 4 – supernatant 
& Stage 5 – precipitate in figure 8). This solution was put in an ultracentrifuge at 20,000 
rpm (41,171 x g) in a Beckman Coulter JA-25.50 rotor at 4oC for 1 hour (Stage 6 – 
supernatant & Stage 7 – precipitate in figure 8). The pellet from this was discarded and the 
supernatant from this was poured into 1L beakers and diluted 10-fold with ddH2O, it was 
left to set for 3 hours. The supernatant was carefully siphoned off (Stage 8 in figure 8) and 
the precipitate was centrifuged at 7800 rpm (10,750 x g) in a Beckman Coulter JA-10 rotor 
at 4oC for 15 minutes. The supernatant from this centrifugation was discarded and the 
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pellet was homogenised (Stage 9 in figure 8) in the least amount of buffer D as possible 
(≤10 ml). This resuspended solution was dialysed overnight against 2L of buffer E, and it 
was changed the next morning and dialysed again for an additional 2 hours.  
Day 3 involved clarification of myosin, spinning the dialysed solution at 20,000 rpm (41,171 
G) at 4oC for 2 hours in a Beckman Coulter JA-25.50 rotor. The myosin was carefully 
removed from the tubing, avoiding the upper fat layer (Stage 10 – supernatant & Stage 11 
– precipitate in figure 8). To determine the concentration and check the purity of the 
myosin from this extraction, it underwent SDS-PAGE gels and spectrophotometry at 280 
nm and 320 nm (to check for myosin and its purity respectively – see table 1) at several 
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Dilution Abs280 Abs320 mg/ml µM 
1:25 0.341 0.93 8.3 16 
1:50 0.191 0.051 9.5 19 
1:100 0.107 0.026 11.4 23 
Average - - 9.7 19.3 
 
Table 2 - Buffers and compositions for purification of muscle myosin II from chicken pectoralis. 
Buffer Composition 
A 150 mM Potassium Phosphate pH 6.7, 
300 mM KCl, 20 mM EDTA, 5 mM 
MgCl2 , 5 mM DTT, 4 mM ATP 
B 60 mM Potassium Phosphate pH 6.7, 1 
M KCl, 20 mM EDTA, 5 mM DTT 
C 25 mM Potassium Phosphate pH 6.7, 
600 mM KCl, 5 mM DTT 
D 50 mM Potassium Phosphate pH 6.7, 3 
M KCl, 5 mM DTT 
E 50 mM Potassium Phosphate pH 7, 600 
mM KCl, 5 mM DTT 
 
Table 1 - Spectrophotometry values to determine the concentration of myosin.  
Serial dilutions were made, allowing three sets of values to average. The absorbances were measured at 
280 nm and 320 nm, using 0.55 as an extinction coefficient for myosin, this allowed for the 
concentration of myosin in mg/ml and as a molarity. 
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8.1.2. Papain digest of Myosin Head 
 
Papain is a proteolytic enzyme derived from papaya that was used to digest full length 
myosin into S1 myosin, whilst retaining the regulatory light chain (RLC) and essential light 
chain (ELC). First, myosin had to undergo deglycerination, this was done according to this 
protocol (Margossian and Lowey, 1982). Dialysis of 30 mg of glycerinated myosin in 12-14 
kDa dialysis tubing was done overnight against 1L of solution A (200 mM ammonium 
acetate, 2 mM MgCl2, 1 mM DTT, pH 7.2). An extra step of dialysis was done the following 
morning with fresh solution A for 2 hours. The myosin suspension has increased in viscosity 
and now it is brought to room temperature.  Solution B (1 mg/ml papain, 5 mM Cysteine, 3 
mM EDTA, pH 6.0) is added (70 µl/ml) to make a final papain concentration of 0.07 mg/ml 
and it was immediately put on a rotating mixer and timed for 10 minutes whilst samples 
were taken at the start and every 5 minutes to provide a time-course gel (see Figure 9). To 
stop the reaction, solution C (100 mM Iodoacetic Acid) was added (50 µl/ml) to reach a 
final iodoacetic acid concentration of 5 mM. This digested suspension was spun down at 
10,000 x g for 30 minutes at 4oC and the supernatant should solely be S1 myosin at a yield 
of 40% of the theoretical value. The supernatant was then purified further by using a 
HiTrap DEAE FF 5 ml column (GE Healthcare) which allowed purification over a 0 KCl to 250 
mM salt gradient in a 50 mM Tris-HCl buffer at pH 8. SDS-PAGE gels (see Figure 9) were 
done to decide which fractions to pool together, and they were stored in 50% glycerol at -
20oC or used in an exchange reaction. 
8.2. Preparation of Thin filament 
8.2.1. Preparation of Actin 
 
Following the myosin preparation, preparation of acetone powder is done. The pulp from 
the myosin preparation is extracted using 50 mM NaHCO3 for 12 minutes using an 
overhead stirrer on a speed which does not create bubbles. It is then filtered using four 
layers of cheesecloth after the extraction and this is done twice. Extraction is repeated 
again but with ddH2O instead of NaHCO3, but the extraction time is shortened to 5 minutes. 
Moving to a fume hood, the extraction process is done with 100% acetone for 10 minutes 
and this is repeated three times until the pulp has turned into somewhat of a damp 
powder. This powder is left on lightly covered tin foil to air-dry overnight. The following 
morning, the powder is weighed and stored in a conical tube in the freezer at -20oC. 
Isolation of actin is done over a 4-day process. Day 1 consists of extraction of the actin 
using extraction buffer (Tris Base 20 mM, CaCl2 0.2 mM, 0.2 mM ATP, 1 mM DTT) on ice 
using an overhead stirrer for 30 minutes (again, on a speed which does not create bubbles). 
The solution is then spun in a JA-10 rotor at 7500 rpm (10,000 x g) for 20 minutes at 4oC 
and then filtered through four layers of cheesecloth – the supernatant is stored on ice and 
then pellet re-extracted as before but for a further 10 minutes following the same 
centrifuging as described above. The supernatants are combined and addition of the 
following: 50 mM KCl, 2 mM MgCl2 and 1 mM ATP are added to polymerise the actin from 
its G monomer (globular) state to its F – filamentous state. Using a stir rod to gently mix the 
solution together it is then left for 2 hours at 4oC and an increase of viscosity should be 
seen. A high salt wash is done by increasing the KCl concentration from 50 mM to 600 mM 
using solid KCl, using a stir bar to gently mix, the solution is mixed for 30 minutes at 4oC, 
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this is to remove tropomyosin. After this, sedimentation of filamentous actin was done by 
spinning it in a Type 45 Ti rotor at 42,400 rpm (209,000 x g) for 1 hour at 4oC, the 
supernatant is removed and then depolymerisation is started. Depolymerisation is done by 
gently scraping the pellet off the tube and homogenising it with 3 ml of cold buffer A per 
gram of acetone powder originally extracted. Once successfully homogenised, it is dialysed 
against 1 L of cold extraction buffer for 1 hour at 4oC and then it is transferred to some 
fresh cold extraction buffer to be dialysed overnight at 4oC. 
Day 2 consists of solely dialysis, whereby you change the dialysis buffer in the morning and 
repeat this every 8 hours in preparation for Day 3. Day 3 is where you clarify G-actin by 
spinning the dialysed solution in a Type 45 Ti rotor at 42,400 rpm (209,000 x g) for 1 hour at 
4oC. The supernatant is then removed into a small beaker and polymerisation is done by 
adding 1 M imidazole and 25 mM MgCl2, this is gently mixed before dialysing this solution 
in 2 L of storage buffer (4 mM imidazole, 0.1 M KCl, 2 mM MgCl2, 1 mM DTT, pH 7) 
overnight at 4oC. Day 4 consists of quantifying the concentration and purity of the actin by 
running SDS-PAGE gels (see figure 10) and using spectrophotometric measurements at A280 
(protein) and A320 (purity). 
 
8.2.2. Preparation of Accessory Proteins 
 
Plasmids containing rabbit α-Tropomyosin and human cardiac troponin complex were 
kindly donated by Professor Mike Geeves. They were transformed into E.coli BL21(DE3) 
strain, expressed and purified by Dr Alessio Inchingolo, these were stored in 3% sucrose, 
flash frozen and stored in the freezer at -80oC at a concentration of 110 µM and 10 µM, 
respectively. 
 
8.3. In vitro motility assay 
8.3.1. Flow chamber design 
 
The flow chamber consists of glass slides (ThermoSci), double sided sticky tape (3M) and a 
22 mm x 22 mm coverslip (glass coverslip). Firstly, glass coverslips are submerged in ddH2O 
and a thin opalescent film of 50 µl nitrocellulose (Sigma-Aldrich) is formed above that, the 
water beneath the film of nitrocellulose is drained and the glass coverslips are allowed to 
dry for 30 minutes before assembling the flow cell. Meanwhile, two pieces of double-sided 
sticky tape (3M) are placed on either side of the glass slide. Once the nitrocellulose glass 




Figure 3 - Projected and assembled schematic views of a flow cell for in vitro motility assays.  
a) shows the projected view of the flow cell, highlighting individual components such as glass slides, 
double-sided tape strips and coverslips. b) is the assembled view which is ready for incubation. 
 
8.3.2. Incubation of flow cell for motility assay 
 
The methods of preparing the flow cell for the motility assay were slightly adapted from 
(Szczesna‐Cordary et al., 2007; Greenberg and Moore, 2010). The following was added to 
the flow cell and incubated at room temperature. Firstly, 30 µl of myosin incubated for 1 
minute (this was done twice), then 30 µl 0.5 mg/ml BSA (Sigma-Aldrich) incubated for 1 
minute (done twice). The unlabelled actin coat was vortexed for 30 seconds to shear the 
actin before adding 30 µl to be incubated for 1 minute (done twice), followed by a 30 µl 
ATP wash (done twice) to release all actin that are attached to active myosin heads. A 30 µl 
1X actin buffer wash was done twice and then TRITC-phalloidin (Sigma-Aldrich) labelled 
actin was very slowly pipetted and incubated for 30 seconds (slow pipetting reduced the 
shearing force on the actin). Another 1X actin buffer wash was done twice to remove any 
free moving actin and to reduce the signal to noise ratio whilst imaging. Finally, three 
washes of 30 µl motility buffer were done because it contains methylcellulose which causes 
a reduction in lateral diffusion of the actin filaments away from the surface as mentioned in 
(Uyeda et al., 1990). 
 
8.3.3. Single molecule fluorescent microscopy 
 
All experiments were conducted on a custom-built oblique angle fluorescence (OAF) 
microscope using an Olympus IX50 inverted microscope frame. The angle of the 
illumination beam allows us to image the surface of the cover slip which is the pinnacle of 
all our surface-based imaging assays. The custom excitation path uses a 488 nm, 561 nm or 
637 nm lasers which passes through an Olympus 1.45NA 100x objective lens. Dependent on 
the Phalloidin based dye used determined what laser would be used for each experiment.  
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Previously described in (Springall et al., 2016), we are able to obtain triple colour images by 
using an Optosplit III (Carin Research, UK). Images were recorded using the Hamamatsu 
Orca Flash4.0 V2 with a 1x1 or 2x2 bin resulting to a 63.2 nm or 162.4 nm camera pixel size, 
respectively. All images and videos were processed using Fiji. 
 
8.4. Regulated Thin Filament tightrope assay 
8.4.1. Flow chamber design 
 
Glass slides (ThermoSci) were drilled to make two 3 mm holes using a Dremel drill with 
diamond drill tips at maximum speed submerged in water and in a 3D printed template 
holder. Drilled slides were washed by soaking them in 100% Acetone (Fisher Chemical) and 
100% Ethanol (Fisher Chemical) overnight on an orbital shaker. Coverslips (ThermoSci) 
were added alongside the drilled slides and they were placed in a plastic beaker, addition 
of 200 ml of 100% acetone and 4 ml (2%) of (3-Aminopropyl) triethoxysilane (APTES) was 
done for the silanization process which allows the subsequent attachment of our silica 
beads to the surface of the flow-cell. Silanization was done for 10 minutes on an orbital 
shaker and it was poured off and rinsed using deionized water. Each slide and coverslip was 
dried with nitrogen gas and placed in a rack to be cured in the oven at 105oC for 1 hour. 
Plastic tubing with a 1.15 mm internal diameter (GE Healthcare) was cut down to an 
appropriate size and by use of a heat gun - one end was flared out. This was done to allow 
the tubing to stay in place whilst adding UV adhesive. UV adhesive was applied to seal the 
tubing to the glass slide. This was placed under a UV lamp for 2 minutes, so the adhesive 
fully dried, the flared-out end of the tubing was cut down using a scalpel to make what will 
be the inside of the flow cell. A double-sided rectangle gasket was placed encompassing 
each hole of the flow-cell and then the coverslip was added to create a flow chamber, this 
is illustrated in Figure 4. 
 
Figure 4 – Projected and assembled schematic views outlining design of a flow-cell and its 
connections to perfusion tubing and the syringe pump.  
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a) shows the projected view of a flow cell, showing individual components such as the coverslip, 
adhesive gasket, drilled glass slide and respective tubing. b) illustrates the assembled product of a 
flow-cell ready for incubation and imaging. 
 
8.4.2. Incubation process for the flow cell 
 
Flow cells are first washed through with 200 µl of deionised water through each port and 
then blocked with 80 µl of methoxypolyethylene glycol 5,000 (mPEG 5000) in proprionic 
acid (Sigma-Aldrich) and left overnight in the fridge at 4oC. Deionised water was then 
pumped through each port again to wash out any excess mPEG and then 80 µl of ABT 
buffer (25 mM KCl, 25 mM Imidazole, 4 mM EGTA, 4 mM MgCl2, 0.1% BSA, 0.1% Tween 20, 
) was pumped through the flow cell and stored overnight in the fridge at 4oC. The flow cell 
is now ready to flow in 100 µl ddH2O washed 5 µm silica beads (Bangs Laboratories) which 
adhere to the silanised coverslip.  
The beads are vortexed for 15 seconds and sonicated for three 1 second pulses at 80% 
amplitude using a before flowing the 100 µl into the flow cell, the flow cell is checked under 
a Nikon light microscope for bead density to ensure there are enough beads close enough 
to suspend the reconstituted thin filament between. The flow cell is then washed with the 
calcium-based buffer (25 mM KCl, 25 mM Imidazole, 4 mM EGTA, 4 mM MgCl2, 100 µM 
CaCl2, 0.1 µM ATP, 100 mM DTT) and subsequently 500 nM of reconstituted filament is 
flowed through in order to suspend the RTFs on a bi-directional loop pumping back and 
forth at a rate of 300 µl/min for 30 minutes before loading the flow cell onto the custom-
built oblique angle fluorescence (OAF) microscope. 
 
8.4.3. Single molecule fluorescence imaging 
 
All experiments were conducted on a custom-built oblique angle fluorescence (OAF) 
microscope using an Olympus IX50 inverted microscope frame. The angle of the 
illumination beam allows us to image the surface of the cover slip which is the pinnacle of 
all our surface-based imaging assays. The custom excitation path uses a 488 nm, 561 nm or 
637 nm lasers which passes through an Olympus 1.45NA 100x objective lens. RTF’s were 
labelled with a combination of Alexa Fluor 633 (Sigma-Aldrich) and Biotin-phalloidin (or 
phalloidin) (Sigma-Aldrich) in a 2:1:0.5 fashion being: actin, biotin-phalloidin (or phalloidin) 
and Alexa Fluor 633 respectively. The reasoning behind dual labelling was due to the 
concentration of the AF633 dye, a low concentration of 3 µM required a high volume to use 
to label in a typical 1:0.5 (actin:dye) fashion which ultimately led to a high amount of 
methanol which distorted the structure of the thin filament and made imaging single 
tightropes difficult.  
Previously described in (Springall et al., 2016), we are able to obtain triple colour images by 
using an Optosplit III (Carin Research, UK). Images were recorded using the Hamamatsu 
Orca Flash4.0 V2 with a 1x1 or 2x2 bin resulting to a 63.2 nm or 162.4 nm camera pixel size, 
respectively. All images and videos were processed using Fiji. 
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8.5. Fluorescent labelling of S1 myosin with mNeonGreen 
8.5.1. Designing RLC-mNeonGreen-6xHis 
 
S1 myosin is inherently a dark protein, to visualise it under the microscope it has to be 
labelled with a fluorophore. In order to do this, S1 has a component termed the regulatory 
light chain (RLC) which can be tagged with a fluorophore and exchanged with wildtype RLC 
allowing us to track its binding, releasing and diffusion under our custom-built OAF 
microscope. Our aim was to design a construct that contains RLC, mNeonGreen as well as a 
His-tag (6xHis) on the end to allow for protein purification. 
PCR was performed twice on previously designed constructs of RLC-mScarlet (pET21a 
vector) and UvrB-mNeonGreen (pET21a vector). For the RLC-mScarlet plasmid, the aim was 
to linearise the plasmid whilst removing the fluorophore mScarlet. For the UvrB-
mNeonGreen plasmid, the aim was to solely isolate and extend mNeonGreen with 
complementary ends to the RLC containing vector so it can act as an insert for the Gibson 
Assembly later on. Once this has been done, it was checked using 1% agarose gels (120 V 
for 30 minutes) and then the rest of the PCR products were run on a full length 0.8% 
agarose gel (120 V for 1 hour) to allow for better separation of any close or unwanted 
bands. The desired bands from the second gel were excised and use of a DNA extraction kit 
(QIAgen) allowed purification of the products for Gibson assembly. The products following 
these processes were ran on a 1% agarose gel (120 V for 30 minutes) (Figures 14 and 15) to 
provide approximate quantification by using a GeneRuler 1 kb DNA ladder (Thermo 
Scientific).  
Gibson Assembly was done using NEBuilder HiFi DNA Assembly Master Mix (NEB), this 
incorporated the extended mNeonGreen insert with the RLC vector. The reaction mixture 
was incubated at 50oC for 15 minutes and following incubation, the assembled product 
(Figure 13) was transformed into AAEC189 competent cells on ampicillin agar plates. 
Colony PCR was done to check whether the insert of the fragment was successful. 
Meanwhile, running a full length 1% agarose gel (Figure 16) and picking a colony to grow 
overnight allows us to check whether the size of RLC-mNeonGreen-6xHis fragment is 
correct and allows us to miniprep the next day to confirm via sequencing. Sequencing was 
provided by Eurofins Genomics and was manually checked using Snapgene. 
 
8.5.2. Expression and purification of RLC-mNeonGreen-6xHis 
 
The plasmid we designed containing RLC-mNeonGreen-6xHis was transformed into BL21 
(DE3) competent cells, streaked against ampicillin agar plates and incubated overnight at 
37oC. The plate was picked for a colony and then the colony was placed in a 1L flask of LB to 
grow to OD600 0.4-0.6 in a shaking incubator at 37oC. Once the desired OD600 was met, the 
1L flask and the incubator was then briefly cooled down to 25oC before the addition of 1 
mM IPTG. The IPTG induction was done at 25oC for 3 hours in a shaking incubator. Samples 
were taken along the way for spectrophotometer measurements and SDS-PAGE gels 
(Figure 18) and after 3 hours the cells were spun down in a JA-10 rotor at 4500 x g for 10 




The pellet was gently resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM 
Imidazole, 5 mM DTT, protease inhibitor, lysozyme, pH 8.0) then the cells are placed in an 
ice bath and are sonicated for 5 minutes on a 30 second on/off cycle with a 55% amplitude. 
The supernatant was then centrifuged in a JA-10 rotor at 4500 x g for 30 minutes and the 
pellet was discarded. The supernatant was then applied to a HisTrap HP 1 ml (GE 
Healthcare) column at a flowrate of 1 ml/min and it was eluted over a gradient of 25 
fractions. SDS-PAGE gels were done to check for purity and to help decide which fractions 
to pool together. The RLC-mNeonGreen-6xHis was finally quantified by spectrophotometry 
at absorbance 506 nm and was stored in 50% glycerol at -20oC, flash frozen in smaller 
aliquots or used to label S1 myosin immediately. 
 
8.5.3. Labelling of S1 with RLC-mNeonGreen-6xHis 
 
Since purified S1 myosin and RLC-mNeonGreen-6xHis were stored in different buffers, 
buffer exchange was done to prepare them for an exchange reaction. Firstly, spin 
concentration using a 50 MWCO Vivaspin 20 (GE Healthcare) column was done to decrease 
the volume of our samples to about 1 ml and it was then loaded onto an equilibrated 
Centripure P5 gel filtration (Generon) column with an exchange buffer (50 mM Potassium 
Phosphate buffer, 600 mM KCl, 10 mM EDTA, 2 mM EGTA). Each step allowed 
quantification of the concentration using a spectrophotometer, using the extinction 
coefficient of mNeonGreen at 506 nm (116000 M-1 cm-1) and S1 at 280 nm (ɛ280=0.83 ml·mg-
1cm-1) (Barua et al., 2012). 
Exchange reactions were set up in a 1:5 molar ratios, the reaction was stopped by the 
addition of 15 mM MgCl2 and each reaction was pooled together. Again, spin concentration 
was done to decrease the volume of our samples and using the Centripure P5 gel filtration 
column, buffer exchange was done into the low imidazole column buffer (50 mM NaH2PO4, 
300 mM NaCl, 20 mM imidazole, pH 8) for the final purification step. 
8.5.4. Purification of S1-mNeonGreen-6xHis 
 
The use of a HisTrap HP 1 ml (GE Healthcare) column allowed the final purification step of 
S1-mNeonGreen-6xHis. This was done over a gradient of 20 mM imidazole to 250 mM 
imidazole allowing sufficient separation over the fractions. Each fraction was quantified via 
spectrophotometry and SDS-PAGE gels were done to help decide which fractions to pool 
together. Pooled fractions were aliquoted, and flash frozen at -80oC. 
 
8.6. Data Analysis 
8.6.1. Data Analysis Workflow 
 
The RTF tightrope assay allows us to visualise the activation of regulated thin filament (RTF) 
at a single molecule level (Desai et al., 2015). This process is very dynamic because in sub-
maximal activation conditions, fluorescently labelled S1 are allowed to bind, release, and 
diffuse across a single RTF. Previous attempts of analysing this data revolved around using a 
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Reversible Jump Markov Chain Monte Carlo (RJMCMC) model to understand the concerted 
release of the thin filament (Inchingolo et al., 2018). However, we have now decided to 
take different approach because by simplifying the analysis process we can interpret the 
data much better. The approach we have taken was to develop an analysis suite which 
allows an increased level of automation by running a combination of Fiji macros, Excel 
formulas and MATLAB scripts. The main aim of this suite (Illustrated in Figure 5) is to 
provide a high throughput approach to extract and analyse data we have obtained from 
imaging. 
 
Figure 5 - Flowchart outlining each step of the new method of data analysis.  
Each step of the data analysis is outlined below alongside what software accompanies it, 1) is where 
we convert imaging data into kymographic projections. 2) Is where we use a MATLAB script to super-
resolve fluorescence spots using the ‘Ezyfit’ toolbox. 3) Using Excel, we are able to filter out 
anomalous Gaussians fits and scale up data to be used in Trackmate. 4) By fitting amplitudes to 
several Gaussians, we are able to create fluorescent thresholds that we can assign a number of 
myosin molecules to. 5) Converting the scaled-up data from the Excel spreadsheet we are able to 
create a scaled-up movie using a MATLAB script. 6) Trackmate is used to track the number of myosin 
spots there are using parameters from the Excel spreadsheet. 7) Using a simple LAP tracker, 
Trackmate can thread spots within predetermined displacement values. 8) Using the threaded data, 
we can develop a transition matrix to determine the probabilities of cluster size changes. 
 
8.6.2. Converting Imaged Data to Kymographic Projections 
 
Firstly, we must extract kymograph data from our imaging videos using Fiji. Whilst playing 
back the videos, bright spots appear to be flashing and moving along the tightrope (seen in 
Figure 6a), this is the active region that we are looking for. A Z-projection of the RTF is done 
to highlight the max intensity of the spots on the tightrope for the entire video (seen in 
Figure 6b), thus, allowing us to visualise the active regions. By highlighting this region, we 
can create a straight line through this active region and then copy it over to the original 
video (seen in Figure 6c and 6d). Once done, we can reslice the video and create a 
kymograph whilst avoiding interpolation (seen in Figure 6e). In order to get a more defined 
kymograph, a rolling ball background subtraction is done at 50 pixels to highlight the active 
regions and remove the majority of the background noise (seen in Figure 6f). Finally, this 
kymograph is converted into a 32-bit format preserving the intensity values and it is saved 




Figure 6 - Converting captured videos into kymographic projections.  
a) highlights the original video captured, note on the top left of the window there are 200 frames for 
this video. b) a Z-projection has been done for the max intensity of fluorescent spots within the 
video, this shows the brightest spots and highlights our active region. c) the active region is then 
highlighted using a straight line to capture all the events within that region. d) copying the straight 
line onto the original video (Shift+E shortcut) allows us to capture the events on the video too. e) we 
are able to create a kymograph avoiding interpolation which shows all the binding events across the 
200 frames. f) final kymographic processing consists of background subtraction using a rolling ball of 
50 px and converting the image to 32-bit to conserve all intensity values. 
 
8.6.3. Super-resolving fluorescent myosin spots 
 
Super-resolving myosin spots is done by the second piece of the suite called ‘The ring’, 
which aims to encompass all the fitting and positional tracking of fluorescent spots on the 
kymograph. It is coded in MATLAB by Dr Neil Kad and allows the fitting of multiple 
Gaussians on each slice of the kymograph. It does this in four steps: 
1. Initial Gaussian Fitting 
2. Threshold filtering the Fit 
3. Finding Peaks 
4. Fitting Peaks 
Firstly, the program allows you to choose the file of interest and then it calculates the mean 
positions and the max intensities of spots for each slice. Secondly, by inspecting the 
intensity values of the kymograph beforehand, you can apply a threshold value to ignore 
intensities that are below said value. For our analysis, we have determined that on average 
fluorescent spots have an intensity that is typically brighter than 100 a.u. and anything 
below is considered as background noise. Doing this allows filtering of the background 
noise which could be mistaken as a myosin intensity peak. After this threshold has been 
applied, the script looks for the number of peaks and sorts each value found in 
chronological order. A toolbox named ‘EzyFit v2.45’ is used to fit each peak to a respective 
Gaussian curve, the script allows up to 20 peaks to be fit simultaneously on one slice of the 
kymograph, but this can be increased further if necessary. After fitting the peaks, a 
plethora of variables will become available in the workspace of MATLAB. The variable of 
interest containing our data is termed ‘fitline’ (highlighted in Figure 7c) which we can take 




Figure 7 - Super-resolving fluorescent myosin spots using a custom MATLAB routine.  
a) shows the first three steps of ‘The ring’, MATLAB reconstructs the kymograph several times by 
fitting an initial gaussian, using a threshold filter and finding precise peaks. b) is the final stage of 
‘The ring’ whereby these peaks are fit using the ‘Ezyfit’ toolbox in MATLAB. c) shows the final 
workspace with all the parameters, the green arrow highlights our parameter of interest – ‘fitline’. 
 
8.6.4. Noise suppression 
 
The MATLAB script uses the ‘Ezyfit’ toolbox and provides unbiased routine fitting which 
may produce some errors. This is cleaned up in the first (Main Analysis) spreadsheet by 
sorting, filtering and scaling up the data, allowing it to be used in Trackmate. The first 
spreadsheet takes the data from the ‘fitline’ variable and it restructures it in a columnar 
format, this allows correct correlation between corresponding amplitude and mean values. 
The amplitudes are filtered to only include Gaussians that are positively fitted (values 
which are greater than zero) and the means are filtered only to encompass Gaussians that 
are within 0 and the maximum width of the kymograph which is variable between each 
kymograph (for example, one kymograph can be 40 px wide x 200 px long). The initial 
filtering of the amplitude and means are separate, so next we combine these filters which 
means if we have a value in the same amplitude and corresponding mean, this value is 
kept, if it is one or the other, it is removed (for example, if mean 1 is present, and 
amplitude 1 is not, the values are not kept, both need to be present to be kept). 
Meanwhile, the frequency of each amplitude is calculated using COUNTIF statements and a 
frequency table is generated and used in the ‘Amplitude Fitting’ sheet. After this, rounding 
to 1 decimal place is done so that the raw intensity values in this data would be counted as 
individual pixels when imported into Fiji. Therefore, to account for sub-pixels, these 
positions are upscaled accordingly by a factor of 10 due to the 1 decimal place rounding, 
this provides us with integers and will be counted as individual pixels in Trackmate. After 
error removal, the final mean and amplitude values are presented at the rightmost part of 
the ‘Main Analysis’ sheet. The threshold value for Trackmate is calculated, this value is 
essentially the lowest mean from the data, this is calculated by using the SMALL formula in 
Excel. Also, the total number of spots that could be seen by Trackmate is calculated, this 
essentially counts the final mean values present using the COUNTIF function, however, 
Trackmate counts spots that move positionally, so if there is a spot that stays in the same 
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position over two frames, it will not be counted as a different spot, hence, when tracking in 
Trackmate, the value may seem less than what it actually is – this calculation solely acts as 
a guideline. Finally, on the ‘Main Analysis’ sheet, the number of spots per slice is calculated 
by COUNTIF functions as well, this also acts as an indicator to see if Trackmate is tracking 
the number of spots per slice correctly. 
The next two sheets are termed ‘Positioning’ and ‘Error Removal’ respectively, as they 
position the mean values to the corresponding amplitude using nested IF functions, and 
then using the IFERROR function to remove error values which are replaced with zeros to 
act as blank pixels. The results from the ‘Error Removal’ sheet are copied to a text file 
which is imported into a MATLAB script described later on. 
 
8.6.5. Fitting Fluorescent Thresholds of Individual Myosin Molecules 
 
The next sheet on the spreadsheet is termed ‘Amplitude Fitting’ and this essentially takes 
the results from the Bin-Frequency table and fits up to 8 Gaussian curves to the raw curve 
(where this can be increased if necessary). It does this by calculating the sum of the 
Gaussians and the sum of the square differences to fit the fitted curve to the raw one that 
was generated, in order to get an accurate fit, Excel’s solver is used. By doing this, we are 
able to transpose the amplitude and mean values, these mean values are considered the 
values that are the intensities that correspond to the number of myosins. Ultimately, we 
are able to make a lookup table which revolves around each myosin intensity being 
surrounded by 2 standard deviations to capture 95% of spots from the mean myosin 
intensities.  
 
8.6.6. Converting Raw Data into a Movie 
 
As aforementioned, the ‘Error Removal’ sheet contains the data we use for this stage. We 
copy it into a text file, this text file is imported to a MATLAB script termed 
‘kymograph2mov’. This MATLAB script essentially takes each slice of the data and converts 
into a movie with the .mj2 file format. The .mj2 file format is used to conserve the intensity 
values of the myosin ‘spots’. 
 
8.6.7. Tracking Fluorescent Myosin Spots using Trackmate 
 
Trackmate is an open-source application for single particle tracking available via Fiji 
(version 5.0.2) (Tinevez et al., 2017). Whilst Trackmate has been mainly used to track 
particles in a 3D space (Jaqaman et al., 2008), we have decided to adjust the use of 
Trackmate to fit our method of analysis. We use Trackmate because previously this was a 
heavily manual process of threading and tracking active regions of thin filament, by using 
Trackmate alongside our analysis suite we are able to create a high-throughput method of 
analysis whilst improving the quality of the results. Trackmate offers various detectors to 
find and track ‘spots’, we’ve decided to use the Laplacian of Gaussian (LoG) detector 
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because it has proven the most accurate detector versus the other ones offered such as the 
Differences of Gaussian (DoG) detector. Adjustable parameters were offered by this 
detector, in which, we decided to choose our estimated spot diameter to be 1 pixel and the 
threshold to be the minimum intensity from the array of intensities from the ‘Main 
Analysis’ sheet. Meanwhile, ‘median filter’ and ‘sub-pixel localisation’ are turned off 
because they are not needed. There are other filter menus after the initial setup, but these 
were also left untouched. Using a simple LAP tracker, we are able to set several parameters 
such as max linking distance (pixel), max gap-closing distance (pixel) and max frame gap for 
gap closing which can allow threading of our ‘spots’. These values are determined from the 
final sheet on the first spreadsheet is termed ‘Average Displacement Length’, this sheet 
essentially takes the measurements of the width of active regions on each kymograph and 
averages the myosin displacement and multiplies it by 10 (scaling as mentioned in section 
8.6.4.) , this value is then used in Trackmate to determine what ‘spots’ are in range to be 
considered in the same track. Ultimately, the configuration of Trackmate has allowed 
consistent threading of ‘spots’ and reports all tracks and corresponding data to an Excel 
spreadsheet.  
  
8.6.8. Threading Fluorescent Myosin Spots using Trackmate 
 
Threading is the process in which we determine identity and position of an individual spot 
over several connected frames. Questions being asked are whether or not between these 
frames has this spot moved and if it has moved; has it joined to another local spot or split 
into two or more spots? These questions can allow us to track and follow the movement of 
each spot frame by frame and the decision-making behind this is mostly automated by 
Trackmate. However, we can adjust parameters and filters to increase the accuracy of the 
threading. Previously, threading each myosin was done manually and a different analysis 
approach was taken as mentioned in section 8.6.1. Tracking individual spots movement at a 
high resolution and over hundreds of frames required us to take a different approach in 
how we can utilise Trackmate and to validate our approach we have ran control simulations 
described in section 8.6.10.  
 
8.6.9. Developing a Transition Matrix 
 
In order to develop a transition matrix, another spreadsheet is used for analysing results 
gained from Trackmate. The second spreadsheet takes the results exported from 
Trackmate (.csv file format) and applies them to an ‘Amplitude Assigning and Classification’ 
sheet, which assigns the number of myosins based on the total intensity exhibited from 
each myosin spot. This is done by the lookup table made in the previous spreadsheet. Once 
the number of myosins are assigned, each track is grouped together by using a FILTER 
formula to show a track up to 50 frames in length (this can be increased if necessary). The 
difference between each frame is calculated using the SUM function and this information is 
used to classify between each frame, what is going on within an active region. 
To do this, we have determined that in these conditions there are four states of myosins 
interaction with thin filament. Firstly, there is activation of the thin filament, this is where 
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one or more myosins are binding to thin filament creating an active region. Secondly, there 
is stepwise detachment of myosin off of thin filament, this means 1-2 myosins are leaving 
the active region of thin filament between each frame. Thirdly, there is a concerted release 
of myosin off of thin filament, this is where 2 or more myosins leave the active region 
between each frame. Finally, there is a chance that there is no change in the number of 
myosins present between each frame so we can classify that as just staying the same.  
So, with these criteria set, simple IF statements are used to classify the meaning of the 
differences between each frame and by doing this, we can see where catastrophic collapse 
is taking place. Whilst doing so, we can remove results where there is no difference of 
myosins between each frame because when applying these results to a transition matrix, 
we are looking at solely the transitions between each addition or removal of myosin(s) and 
therefore the probability of no changes is not looked into for our studies. Another 
consideration we had to make was that Trackmate tracks each track until there is no local 
myosins to thread together anymore, therefore, the active region has ended. However, 
when looking at the results the data shows a normal active region and does not show the 
complete end of the active region. To accommodate for that, the ending of each track has 
been supplemented with a zero to show that from the final spot of myosin to the end the 
active region has collapsed completely.  
With all these considerations being made, we have results which we can apply to our 
transition matrix on the next sheet. This sheet takes the final results from each track and by 
using COUNTIF functions, we are able to quantify the number of myosins transitioning 
between each frame. By doing so, we can work out the probability of how likely it is for a 
specific cluster to start at and where it would end at.  
 
 
8.6.10. Analysis Suite Validation 
 
The movement of myosin along RTF’s is a very spontaneous process, in order to determine 
if our method of analysis works both accurately and effectively, controls were done to 
simulate what could potentially happen in our metastable conditions. A track is defined as 
a single spot along several frames that has been followed and threaded by Trackmate. A 
myosin molecule can join another track, split into two or more tracks, multiple tracks can 
move in parallel simultaneously, and all conditions can have a random level of unbiased 
bidirectional displacement (Desai et al., 2015) between each frame. 
Here I will outline 3 scenarios that we can anticipate seeing in actual data. A single track 
can remain static over a period of frames. A single track can split, hence generating two or 
more tracks or the opposite can occur where two tracks spatially close enough can join 
together and merge into a single track. Whilst bidirectional displacement of myosin 
molecules occurs, this is accommodated for in section 8.6.7 
We have generated control scenarios that are 20 frames each – in turn giving us enough 
frames to provide splitting or merging two tracks for example. The aim of these control 
scenarios is to validate the accuracy of our analysis approach by comparing the positional 
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and intensity values we have inputted versus what has ultimately been tracked and 
threaded by Trackmate. This is illustrated in section 9.2.1. 
In every case, our method of analysis gave us 1:1 tracking when using Trackmate. By 
calculating the difference between the inputted data versus the data we gained from 
tracking, the closer the value is to 0, the closer the tracked positional value is to the 
inputted value. In all cases these differences were 0 and the corresponding intensity values 




























9.1. Extraction and Purification Analysis: 
9.1.1. Extraction of myosin from chicken pectoralis 
 
Myosin was extracted from chicken pectoralis; the process took 3 days starting off with 
335.8 g of tissue and ending with 12.2 g (~ 12 ml) of 19.3 µM myosin, providing a 
percentage yield of 3.6%. A time course of the extraction process was done where samples 
were taken across the process and an SDS-PAGE gel was done at the end (see figure 8). In 
Figure 8, our lane of interest is Stage 10, which is the final step in the clarification of 
myosin, there are several bands present labelled 1-5 which consists of myosin’s heavy 
chains, tropomyosin, actin, ELC, and RLC, respectively. Considering this gel has overloaded 
samples, we can see faint bands of actin and tropomyosin, but we can consider the 






In addition to the SDS-PAGE gel, spectrophotometry was done to determine the 
concentration of myosin. In order to determine the molarity of the myosin, the molecular 
Figure 8 - 15% SDS-PAGE gel showing a chronological compendium of processes to extract myosin from 
chicken pectoralis.  
Banding patterns are related to actomyosin products, throughout the extraction process – each stage is 
further described in section 8.1.1. Although this gel was overloaded, it still highlights the bands of interest 
in Stage 10. Stage 10 shows 5 bands of interest, where 1 is the heavy chain of myosin (220 kDa), band 2 is 
actin (42 kDa), band 3 is tropomyosin (65 kDa),  band 4 is the essential light chain (22.8 kDa), and band 5 
is the regulatory light chain (18.8 kDa). 
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Dilution Abs280 Abs320 mg/ml µM 
1:25 0.341 0.93 8.3 16 
1:50 0.191 0.051 9.5 19 
1:100 0.107 0.026 11.4 23 
Average - - 9.7 19.3 
 
9.1.2. Papain digest of full-length myosin into S1-myosin 
 
Extracted myosin must be digested into S1-myosin to be used in subsequent exchange 
reactions that fluorescently label it for our studies. Papain is the proteolytic enzyme that 
has proven to be consistent and useful for cleavage of full-length myosin into S1-myosin. 
Figure 9 shows a time course of the digestion and although this gel has been overloaded 
and HMM can be seen labelled band 1, however its intensity in comparison to the start of 
the process has dramatically decreased suggesting the concentration of it is negligible. 
Table 2 - Spectrophotometry values to determine the concentration of myosin.  
Serial dilutions were made, allowing three sets of values to be averaged. The absorbances were 





Figure 9 - 10% SDS-PAGE gel showing the time-course of myosin digestion using papain.  
This is where we took samples every 5-minutes, a different composition of components can be seen 
over time. In our final sample, we spun down the S1 after an overnight dialysis step in preparation 
for further column purification. In the final ‘Post spin’ well, we can see four main bands of interest. 
Again, this gel has been overloaded but we can see band 1 being some remnants of heavy chain 














9.1.3. Purification of actin from acetone powder 
 
Acetone powder is derived from the pulp saved from the myosin preparation. It was 
processed via a series of steps into actin which is seen in ‘Stage 7’. The arrow indicates 
actin which is about 42 kDa in size.  
 
Figure 10 - Time-course of actin preparation from acetone powder.  
This shows the different stages when preparing actin from acetone powder, resulting in the final 
well (Stage 7) being relatively pure despite overloading of wells. The arrow indicates actin with the 









9.1.4. Creating the RLC-mNeonGreen-6xHis plasmid 
 
We were successfully able to create this RLC-mNeonGreen-6xHis plasmid by using two 
constructs, one being a plasmid with RLC attached to mScarlet (see Figure 11), the other 
being a plasmid with a protein called UvrB attached to mNeonGreen (see Figure 12). The 
aim was to use Polymerase Chain Reaction (PCR) to eliminate the mScarlet in the first 
plasmid and in the other plasmid the plan was to conserve only mNeonGreen whilst adding 
extensions that are complementary to the RLC plasmid. By doing this, we have created a 
vector and an insert, which are the RLC plasmid and extended mNeonGreen, respectively. 
Now, we can use a Gibson Assembly process to connect the two together, use colony PCR 
to detect the size of our new plasmid, to then miniprep and sequence our RLC-
mNeonGreen-6xHis plasmid. Each step is outlined below. 
 
 
Figure 11 - RLC-mScarlet plasmid map.  
This illustrates the vector that we are starting with before linearisation, the aim is to remove the 
mScarlet portion (coloured red). 
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This is the RLC-mScarlet plasmid, which will act as our vector for our final product. The aim 
is to remove the mScarlet via PCR whilst retaining all other features including the GAP 
sequence prior to the mScarlet and the AviTag, 6xHis and TEV site after it. Also, it has the 
ampicillin resistance gene so we can selectively choose for it when conducting expression 
and purification of the protein.  
 
Figure 12 – This is the UvrB-mNeonGreen plasmid map.  
The aim for this plasmid would be to isolate the mNeonGreen portion with primers that extend to 
create a complementary overhang to the linear vector we made previously. 
 
This is the UvrB-mNeonGreen plasmid, which contains the mNeonGreen which we want to 
isolate, using PCR we are able to do so, and we are able to create extensions on the 




Figure 13 - This is the desired plasmid, RLC-mNeonGreen.  
After several PCR reactions and Gibson Assembly, we aim to have this as a plasmid. This has been 
confirmed via sequencing. 
 
Figure 13 shows the desired plasmid we aim to create from dissecting and combining the 
two plasmids mentioned earlier. This plasmid has successfully been made via Gibson 







Figure 14 - Using PCR to remove mScarlet from RLC-mScarlet. 
 a) Highlights the initial PCR reaction, the final well shows our desired band, but there seems to be 
smearing at the higher molecular weights are present as well as primer dimers at the end of the gel. 
However, in b) this is cleared up by using a QIAgen DNA extraction and purification kit to solely 




Figure 15 - PCR of UvrB-mNeonGreen to isolate mNeonGreen and create complementary 
overhangs to the linearised vector.  
a) Shows the initial PCR reaction, with our desired PCR product highlighted with the arrow, however, 
primer dimers are seen below so it was decided a PCR clean-up was necessary. b) Shows the clean 
isolate of mNeonGreen with complementary overhangs. 
 
Standard PCR reactions were done for both Figures 14 and 15, in both cases we do see 
primer dimers and a varying degree of ‘smearing’, however, this is not an issue due to Gel 
Extraction PCR purification kits provided by QIAgen. The desired band can be cut out using 
a transilluminator and purified as seen in part b) of each Figure 14 and 15. Their 
concentrations have been quantified via spectrophotometry and are the following: Vector 




Figure 16 - Colony PCR of RLC-mNeonGreen after Gibson Assembly.  
Three out of four colonies have our desired plasmid, showing a consistent banding pattern and it 
follows a similar size as the control which is RLC-mScarlet. The bands of interest are highlighted by 
the arrow. Colonies 1 and 4 were chosen to miniprep as colony 2 was fainter than the rest and 
colony 3 did not contain our plasmid of interest. 
 
Colony PCR is a convenient procedure to determine whether a Gibson Assembly has been 
successful after transformation. Using primers that can seek out our RLC-mNeonGreen 
enables us to see it amplified on our agarose gels. In addition to visualising it on a gel, each 
colony has been streaked onto an agar plate with complementary antibiotic resistance and 




Figure 17 - Miniprep of Colonies 1 and 4.  
Successful minipreps can be seen where the arrow highlights the band of interest being our RLC-
mNeonGreen.  
 
Considering our colony PCR was successful, the colony was grown in LB broth and plated to 
ultimately be miniprepped using a QIAgen Miniprep Kit. Using a Expedion Versawave 2 
spectrophotometer, we are able to quantify our miniprepped plasmid. We achieved 70 
ng/µl concentrated plasmid which seems plausible due to the intensity of the bands in 
Figure 17. After the successful miniprep, we sent a sample off to be sequenced by Eurofins 











9.1.5. Expression of RLC-mNeonGreen-6xHis 
 
Typical expression of a protein would not yield a significant amount of our desired protein 
of interest from our plasmid. Therefore, we use a compound called Isopropyl β-d-1-
thiogalactopyranoside (IPTG) which essentially mimics allolactose from the lac operon and 
induces high levels of protein expression. This in turn allows a significant increase of our 
protein of interest as seen in Figure 18.  
 
Figure 18 - Time-course 12.5% SDS-PAGE gel of expression and induction of RLC-mNeonGreen 
using IPTG.  
A three-hour induction with IPTG was done to induce protein expression, our protein of interest was 
expressed as highlighted by the arrow. Subsequent wells are labelled accordingly and are in 
reference to purification of RLC-mNeonGreen. The intense band appearing from sonication and 




9.1.6. Purification of RLC-mNeonGreen-6xHis 
The final step revolves around purifying our expressed RLC-mNeonGreen-6xHis, this is done 
by immobilised metal affinity chromatography (IMAC). Where a prepacked HisTrap column 
(GE Healthcare) allows immobilised Nickel to bind and release our His-tagged protein over 
an elution gradient.  
 
Figure 19 - 12.5% SDS-PAGE gel showing an elution profile for purification of RLC-mNeonGreen-
6xHis.  
Using a GE Healthcare HisTrap HP protein purification column allowed separation of our RLC-
mNeonGreen-6xHis protein over an elution gradient. Fractions 5-23 were pooled, and 
spectrophotometry was done to determine its final concentration of 1.62 µM. 
 
9.2. Data Analysis: 
9.2.1. Validating the analysis methodology 
 
In order to determine if our method of analysis is accurate, we conducted three sets of 
controls, as describe in section 8.6.10. The controls were upscaled from 30 px width to 300 
px, and Trackmate successfully tracked and threaded each track with correct intensity and 
positional values. For illustrative purposes, an example of a kymograph has been shown in 
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Figure 21, where there are there are plenty of individual spots that are super-resolved by 
our analysis process to be tracked using Trackmate. 
 
 
Figure 20 - Simulated kymographs to act as controls to determine the accuracy of Trackmate 
tracking and threading.  
Where a) is a track of simulated fluorescent myosin as a static straight line, b) is simulated myosin 
departing and splitting into two tracks and c) is the opposite where initially two tracks join together 
and merge into a single track. The kymographs have been upscaled by a factor of 10 to consider sub-
pixels, where the original scale was 30 px wide by 20 px length, it is now 300 px wide and 20 px 
length.  
 
Figure 21 - Example before and after kymographs illustrating the kymographic data in full that 
would be tracked using Trackmate.  
Kymographic data has been processed by our method of analysis (left to right), prior to using 
Trackmate this is something that would be sliced into their respective frames and converted into a 
.mj2 movie. For illustrative purposes, this kymograph is not scaled up by a factor of 10. The left 
kymograph shows the kymographic data in result from initial conversion of imaged data to 
kymographic projections. On the right is after image processing and analysis, an illustration of what 
the data would look like if not scaled up as mentioned previously.  
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9.2.2. Thin filament supplemented with tropomyosin 
To investigate the propensity of catastrophic collapse, videos were analysed from a range 
of S1 myosin concentrations (5-20 nM), at metastable conditions of 5 nM S1, clusters were 
extremely sparse and imaging conditions were subject to high background noise, making it 
difficult for our analysis suite to pick out individual myosin clusters. To overcome this, we 
found a ‘sweet-spot’ of 15 nM S1 to clearly visualise and determine the transitioning of 
cluster sizes.  
 
Figure 22 - Measured transitions between cluster sizes of tropomyosin supplemented RTFs.  
Our new method of analysis allows us to get this set of data. Whereby, this transition matrix shows 
us the probability of starting at 1 myosin and ending at a maximum cluster size of 6 myosins. The 
central diagonal zero shows that the probability of a molecule staying the same size is not 
considered because it is not a transition between cluster sizes. The starting cluster size of zero is 
omitted because we are unable to determine when a track starts. Final cluster sizes show that 
accelerated release of myosin is mediated mostly by tropomyosin. Data obtained here was at 15 nM 
S1-GFP at 0.1 µM ATP (N = 10). 
9.2.3. Thin filament supplemented with tropomyosin and troponin 
 
To investigate the propensity of catastrophic collapse, videos were analysed at metastable 
conditions of 5 nM S1, 0.1 µM ATP and pCa 6. In comparison to Fig 22, catastrophic collapse 
seems to have an elevated final cluster size of two myosins suggesting an intermediate 
state (an energy trap) to catastrophic collapse mediated by the presence of troponin. 
However, further investigations using super-resolution techniques would be required to 
delve deeper to this initial observation. 
 
Figure 23 - Measured transitions between cluster sizes for tropomyosin and troponin 
supplemented RTFs.   
Our new method of analysis allows us to get this set of data. Whereby, this transition matrix shows 
us the probability of starting at 1 myosin and ending as maximum of 6 myosins. The central diagonal 
zero shows that the probability of a molecule staying the same size is not considered because it is 
not a transition between cluster sizes. The starting cluster size of zero is omitted because we are 
unable to determine when a track starts. Data obtained here was at 5 nM S1-GFP at 0.1 µM ATP (N = 
14). 
0 1 2 3 4 5 6 Legend
1 0.38 0.00 0.34 0.12 0.10 0.04 0.03 0.00
2 0.30 0.36 0.00 0.15 0.11 0.04 0.04 0.08
3 0.25 0.26 0.31 0.00 0.13 0.02 0.03 0.15
4 0.26 0.26 0.25 0.15 0.00 0.04 0.03 0.23
5 0.27 0.31 0.26 0.08 0.05 0.00 0.02 0.30
6 0.25 0.32 0.26 0.06 0.05 0.05 0.00 0.38











0 1 2 3 4 5 6 Legend
1 0.26 0.00 0.56 0.10 0.07 0.01 0.00 0.00
2 0.37 0.33 0.00 0.17 0.09 0.02 0.01 0.11
3 0.21 0.18 0.52 0.00 0.07 0.01 0.01 0.22
4 0.16 0.19 0.43 0.17 0.00 0.05 0.01 0.33
5 0.17 0.15 0.41 0.11 0.15 0.00 0.01 0.45
6 0.18 0.11 0.38 0.15 0.13 0.05 0.00 0.56













9.2.4. Catastrophic collapse at varying cluster sizes 
Catastrophic collapse has been measured by using the values from the first column of the 
transition matrices from Figures 22, 23 and from previous studies.  
 
Figure 24 – A graph illustrating the probability of predicted and measured catastrophic collapse of 
RTFs.  
The first column from Figures 22 and 23 are used to illustrate black dashed line with circle points and 
the solid black line with square points respectively, previous studies results (Inchingolo et al., 2018) 
are shown in the blue dotted line with triangle points.. Essentially, we can see that on average thin 
filament supplemented with tropomyosin only is sufficient for the concerted release of myosin as we 
see higher probabilities of measured catastrophic collapse. 
10. Discussion 
 
The activation and deactivation of thin filament has been studied extensively over the years 
(Geeves and Lehrer, 1994; Maytum et al., 1999; Desai et al., 2015; Inchingolo et al., 2018; 
Inchingolo et al., 2019), advances in structural studies (Galińska-Rakoczy et al., 2008; Ratti 
et al., 2011; Yang et al., 2014; Von Der Ecken et al., 2015) provide ideas on the regulatory 
aspect of muscular contraction. Whilst heart diseases such as HCM are still prevalent, it 
provides an urgency to understand the fundamental mechanism of muscular contraction. 
Our studies aim to provide a mechanistic insight on this whilst investigating a newly 
discovered phenomenon termed catastrophic collapse. Regulated thin filament in our in 
vitro system provides us the ability to visualise the cooperative activation, stepwise 
deactivation, and catastrophic collapse of an active myosin cluster. RTFs consists of the 
regulatory components tropomyosin and troponin which can sense calcium to control the 
activation and deactivation of thin filament. Our method of analysis allows us to observe 
these clusters fluctuating in size and in some cases collapsing entirely. After a closer 
inspection of our results using transition matrices, we see that there is a higher proportion 
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than traditional stepwise deactivation. This was suggested in previous studies using the 
RJMCMC approach (Inchingolo et al., 2018), and our method of analysis not only confirms 
the previous results but enhances it by looking at not only RTFs with troponin and 
tropomyosin but thin filament with just tropomyosin. The reasoning behind looking at both 
can show us the importance of these regulatory factors during catastrophic collapse and 
can allow us to get a better understanding of heart diseases such as hypertrophic 
cardiomyopathy (HCM). 
Our well-rounded approach to this study involves looking at myosin interactions on all the 
possible thin filament compositions; free thin filament (without tropomyosin and 
troponin), thin filament supplemented with tropomyosin and thin filament with both 
tropomyosin and troponin. However, without the regulatory proteins to control myosin 
binding in free actin, it would not provide the metastable environment needed to 
investigate the cooperative activity of myosin. In previous studies, it has been shown that, 
free actin even in the presence of a low myosin concentration (1 nM) has extremely 
frequent myosin binding (Desai et al., 2015). Therefore, we can deduce that free actin is 
not a state in which provides these conditions to allow us to investigate our hypotheses. 
This further supports our hypotheses that the concerted release of myosin revolves around 
the presence of the regulatory proteins tropomyosin and troponin.  
Tropomyosin accelerates catastrophic collapse: 
Tropomyosin is considered as a rigid gatekeeper (Sousa et al., 2010) meaning it has an 
effect on thin filament activation. Studies have considered tropomyosin to be a semi-rigid 
molecule by conducting various measurements of its persistence length (Swenson and 
Stellwagen, 1989; Phillips and Chacko, 1996; Li et al., 2010b; Sousa et al., 2010), its rigidity 
has been considered enough to act as a  cooperative unit allowing shifting between 
regulatory states (Li et al., 2010a). Thin filament supplemented with tropomyosin only, 
lacks the troponin complex to calcium sense and regulate conformational change along thin 
filament. Therefore, we can hypothesise that tropomyosin alone on thin filament is capable 
of accelerating catastrophic collapse, shifting itself into the blocked state of the three-state 
model. Recent studies illustrate this using molecular dynamics and cryo-EM (Kiani et al., 
2019)and our analysis support this and shows that tropomyosin alone has a high chance to 
orchestrate catastrophic collapse (Figure 24). Beneath the zeroed diagonal in the transition 
matrix, shows a high probability of finishing at a lower cluster size than what the cluster 
size started at, this is highlighted by the varying degrees of red in Figure 22. This suggests 
there is a higher probability of myosin molecules being shifted off an active region. This 
supports our hypothesis, because we can see that tropomyosin alone can cause thin 
filament to shift towards the blocked state causing catastrophic collapse.  Tropomyosin is 
able to oscillate laterally over thin filament (McKillop and Geeves, 1993), it is believed that 
structural studies have underestimated the stiffness of tropomyosin due to their 
measurements of the persistence length as a straight rod instead of its superhelical 
conformation (Lehman et al., 2020). Therefore, we can suggest that now more realistic 
considerations of tropomyosin’s curved superhelical persistence length of 423 nm leads to 
reasoning that tropomyosin is stiffer and causes an increased likelihood of being in a B-
state position. Where the B-state position (Lehman et al., 2009) of tropomyosin is 
comparably the blocked state of the three-state model of thin filament activation. 
The troponin complex has a tighter regulation on catastrophic collapse: 
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Thin filament was also supplemented with both tropomyosin and troponin; this provides us 
all the necessary components for thin filament activation. Whereby RTFs are in equilibrium 
between closed and open state due to the local presence of ATP, calcium and myosin. 
Figure 24 shows that there is a decrease in catastrophic collapse upon the addition of 
troponin, this suggests that troponin can sense calcium in our metastable conditions, 
allowing tropomyosin to be more inclined to move between the closed and open states. On 
a mechanistic level, we can suggest that the presence of activated troponin allows 
tropomyosin to stay in an open conformation allowing myosin to bind and release as 
normal. However, as the thin filament moves into the closed state, there is a chance that 
troponin may deactivate causing tropomyosin to release all remaining myosin attached 
onto thin filament. Structural studies have determined that the tip of the TnI domain 
interacts with tropomyosin and stabilises the blocked state configuration (Galińska-Rakoczy 
et al., 2008), which allows us to suggest that if we are in the closed state and troponin C 
deactivates, TnI will stabilise the blocked state configuration thus enabling catastrophic 
collapse. We can suggest that the troponin complex acts as a regulator for catastrophic 
collapse because of the balancing that is done between all three subunits of troponin. 
Whilst TnC has an increased affinity for Ca2+ ions (Galińska-Rakoczy et al., 2008), TnT 
structurally strengthens tropomyosin to act as a cooperative unit (Sousa et al., 2010), and 
TnI in the closed state enables the shift of tropomyosin into the blocked state (Galińska-
Rakoczy et al., 2008). We have shown that the addition of the troponin complex decreases 
the probability of catastrophic collapse occurring but does not completely abolish it. The 
fact that catastrophic collapse can occur suggests that it is a necessary process to maintain 




Our study combines single molecule microscopy and a powerful analysis suite to investigate 
the concerted release of myosin on regulated thin filament. Developing a new method of 
analysis enables us to provide a high throughput and simpler approach to processing our 
imaging data. The new method of analysis has illustrated the prevalence of catastrophic 
collapse in regulated thin filaments. Following the previous studies using the RJMCMC 
approach (Inchingolo et al., 2018), our data falls in line with what was previously stated and 
develops it by looking into individual components of regulation such as tropomyosin. The 
surprising finding from our results is that thin filament only supplemented with 
tropomyosin seem to have a higher probability of catastrophic collapse. This study can act 
as an insight on diseases such as hypertrophic cardiomyopathy (HCM) which has been seen 
to be caused by molecular insults with tropomyosin. The E180G mutation on tropomyosin 
causes a reduced rigidity of tropomyosin (Li et al., 2012) which causes an impairment of 
muscular relaxation. Catastrophic collapse can be considered as an essential process to 
ensure muscular relaxation is not compromised and this phenomenon can provide a 
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